Is Western Digital An Ideal Acquisition Target? [View article]
Both STX and WDC are insanely low priced, even if markets for HDD would further decline (what i dont believe will happen). I'm long STX and holding on to them for the long term.
Natural Gas Rigs: Headed Towards A Shortage - Part III [View article]
great article
Can't say i'm in line with analyst expectations for CJES in 2013 and see only more growth in the near future. If that growht does not come from more HP it will come because they keep offering a more complete service, what results in better prices they can demand.
Buy Seagate For A 100% Return In 2 Years [View article]
Dont forget to mention the SSHD technology seagate starts to use. The future of HD's might lay there, the best of SSD's and HD's compared: more storage, less bottleneck and at a lower price then the SSD's.
PDL BioPharma (PDLI): Q2 EPS of $0.52 beats by $0.08. Revenue of $12.9M (+3.1% Y/Y) in-line. Shares +1.1% AH. (PR) [View news story]
"On June 8, 2012, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab). Perjeta is approved in combination with Herceptin ® and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Genentech notified PDL on June 18, 2012, that Perjeta is a licensed product. PDL will receive royalties on sales of Perjeta in the quarter following the first quarter of Perjeta sales in accordance with Genentech’s license agreements with PDL."
is this product part of the queen et al patent or is this one seperated from that group?
Centrotherm Photovoltaics Bankruptcy Places Yellow Flag On GT Advanced Technologies [View article]
I do agree its a though market to be in right now, but the thiong about bankruptcies is that after a wave of those is over that the survivors come out stronger. Imho GTAT might be one of those survivors
It Isn't How Much You Make - It's How Much You Keep [View article]
For the last week I gave the idea of shorting hdge some thought. Because that ETF just shorts some positions that thay think will do worse then the market when the market turns bearish those positions also have some more up potential when the market turns again. what will give them a stronger drop then the s&p will go up at the same time. You also get another bonus because they have a relatively high cost structure, the more short positions on it the higher the cost per outstanding share
George Soros' remarkable speech on the "political bubble" of the EU: "The (current) political dynamic makes the disintegration of the EU just as self-reinforcing as its creation has been ... (however) the likelihood is that the euro will survive because a breakup would be devastating not only for the periphery, but also for Germany." He gives the Germans 90 days to come around. Worth the full read. [View news story]
Give germany 90 days ... YES, germany was the" big problem to begin with, maybe the rest of Europe should look at germany and see what they have done sinse problems started and try to learn from them.
Is Western Digital An Ideal Acquisition Target? [View article]
I'm long STX and holding on to them for the long term.
Natural Gas Rigs: Headed Towards A Shortage - Part III [View article]
Can't say i'm in line with analyst expectations for CJES in 2013 and see only more growth in the near future. If that growht does not come from more HP it will come because they keep offering a more complete service, what results in better prices they can demand.
Buy Seagate For A 100% Return In 2 Years [View article]
PDL BioPharma (PDLI): Q2 EPS of $0.52 beats by $0.08. Revenue of $12.9M (+3.1% Y/Y) in-line. Shares +1.1% AH. (PR) [View news story]
in combination with Herceptin ® and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer who have
not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Genentech notified PDL on June 18, 2012, that Perjeta is a licensed product. PDL will receive royalties on sales of Perjeta in the quarter
following the first quarter of Perjeta sales in accordance with Genentech’s license agreements with PDL."
is this product part of the queen et al patent or is this one seperated from that group?
Centrotherm Photovoltaics Bankruptcy Places Yellow Flag On GT Advanced Technologies [View article]
It Isn't How Much You Make - It's How Much You Keep [View article]
You also get another bonus because they have a relatively high cost structure, the more short positions on it the higher the cost per outstanding share
George Soros' remarkable speech on the "political bubble" of the EU: "The (current) political dynamic makes the disintegration of the EU just as self-reinforcing as its creation has been ... (however) the likelihood is that the euro will survive because a breakup would be devastating not only for the periphery, but also for Germany." He gives the Germans 90 days to come around. Worth the full read. [View news story]
YES, germany was the" big problem to begin with, maybe the rest of Europe should look at germany and see what they have done sinse problems started and try to learn from them.
LRAD Corporation Is Being Undervalued By Investors [View article]